Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Change in Acquisitions & Divestments: 2017-2022

Historic Change in Acquisitions & Divestments for Arcus Biosciences (RCUS) over the last 6 years, with Sep 2022 value amounting to $228.0 million.

  • Arcus Biosciences' Change in Acquisitions & Divestments rose 70.93% to $228.0 million in Q3 2022 from the same period last year, while for Sep 2022 it was $608.8 million, marking a year-over-year decrease of 18.19%. This contributed to the annual value of $690.1 million for FY2021, which is 124.53% up from last year.
  • As of Q3 2022, Arcus Biosciences' Change in Acquisitions & Divestments stood at $228.0 million, which was up 34.93% from $169.0 million recorded in Q2 2022.
  • Arcus Biosciences' Change in Acquisitions & Divestments' 5-year high stood at $251.4 million during Q1 2021, with a 5-year trough of $25.6 million in Q1 2018.
  • Moreover, its 3-year median value for Change in Acquisitions & Divestments was $133.4 million (2021), whereas its average is $135.3 million.
  • Its Change in Acquisitions & Divestments has fluctuated over the past 5 years, first soared by 411.42% in 2021, then tumbled by 62.68% in 2022.
  • Arcus Biosciences' Change in Acquisitions & Divestments (Quarterly) stood at $42.3 million in 2018, then spiked by 31.59% to $55.6 million in 2019, then soared by 209.42% to $172.0 million in 2020, then tumbled by 31.45% to $117.9 million in 2021, then skyrocketed by 70.93% to $228.0 million in 2022.
  • Its Change in Acquisitions & Divestments was $228.0 million in Q3 2022, compared to $169.0 million in Q2 2022 and $93.8 million in Q1 2022.